
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934**

For the month of December 2024

Commission File Number: 001-41115

GENENTA SCIENCE S.P.A.
(Translation of Registrant's Name into English)

**Via Olgettina No. 58
20132 Milan, Italy
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

This report on Form 6-K is incorporated by reference into the registrant's registration statement on Form F-3 (File No. 333-271901).

Other Events

AGC Letter of Intent Amendment

As previously reported in its Report on Form 6-K furnished on November 14, 2024, on October 31, 2024, Genenta Science S.p.A. (“Genenta”) entered into a letter of intent (the “LOI”) with AGC Biologics S.p.A. (“AGC”), pursuant to which Genenta and AGC agreed to negotiate the terms of a development and manufacturing services agreement for Genenta’s cell therapy products (the “Proposed Agreement”) and to execute the Proposed Agreement by December 15, 2024 (the “Negotiation End Date”). On December 11, 2024, the parties amended the LOI (the “LOI Amendment”) to extend the Negotiation End Date to December 20, 2024, resulting in a five-day extension.

The above description of the LOI Amendment is qualified in its entirety by reference to the LOI Amendment, a copy of which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Exhibits

Exhibit No.	Title
--------------------	--------------

10.1	<u>Letter of Intent Amendment, dated December 11, 2024, between AGC Biologics S.p.A. and Genenta Science S.r.l.</u>
------	---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

GENENTA SCIENCE S.P.A.

Date: December 13, 2024

By: /s/ Pierluigi Paracchi

Pierluigi Paracchi, Chief Executive Officer



11 December 2024

Mr. Pierluigi Paracchi
Genenta Science S.r.l

Re: AMENDMENT to the Letter of Intent (this "LOI Amendment") between AGC Biologics S.p.A. ("AGC") and Genenta Science S.r.l. ("Genenta") concerning cell therapy GMP manufacturing

Dear Mr. Paracchi:

Genenta and AGC have entered into a Letter of Intent dated effective 04 November 2024 (the "LOI") and now wish to amend the LOI.

Genenta and AGC are currently negotiating a Second Amendment (the "Amendment") to Development and Master Services Agreement that the parties have entered into effective as of 06 March 2019 (the "Agreement"). The Amendment will amend the Agreement to include terms and conditions to reserve an Exclusive GMP Suite for Genenta with trained full-time equivalents.

Under the terms of the LOI, the Amendment must be fully executed by 15 December 2024 (the "Negotiation End Date"), unless extended by the parties. The parties now wish to extend the Negotiation End Date to 20 December 2024. Except as otherwise set forth in this LOI Amendment, the terms of the LOI remain in full force and effect.

Any and all information exchanged between Genenta and AGC during the term of the LOI, as amended by this LOI Amendment, shall be subject to the confidentiality and non-disclosure agreement between the parties in effect as of the execution date of this LOI Amendment.

This LOI Amendment may be signed electronically and executed in any number of counterparts, each of which shall be deemed an original, and all of which, taken together, shall constitute one and the same agreement. This LOI Amendment shall be effective upon full execution by email or original.

Sincerely,

DocuSigned by:


0312CB4269524EE...

Luca Alberici

Managing Director
AGC Biologics S.p.A.

AGREED AND ACCEPTED

Genenta Science S.r.l.

Firmato da:

By: **PIERLUIGI PARACCHI**

Name: **PIERLUIGI PARACCHI**

Title: **CEO**

Date: **12/12/2024**